Summary
Thermo Fisher Scientific Inc. (TMO) reported solid financial results for the first quarter of 2012, with revenues growing 14% year-over-year to $3.10 billion, driven by contributions from recent acquisitions like Phadia and Dionex, as well as organic growth in existing businesses. Net income increased to $277.3 million, or $0.75 per diluted share, up from $252.2 million, or $0.64 per diluted share, in the prior year's quarter. The company demonstrated strong operational cash flow generation of $392 million. Management expressed confidence in the company's liquidity and ability to meet future cash requirements, supported by existing cash, operating cash flow, and new revolving credit facilities. The company is actively managing its business through ongoing restructuring efforts aimed at streamlining operations and achieving cost efficiencies, with approximately $70 million in additional charges anticipated for the remainder of 2012. Despite increased interest expenses related to debt financing for acquisitions, the overall financial health appears robust. Investors should note the company's strategic focus on integrating acquisitions and driving organic growth across its three key segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services.
Financial Highlights
56 data points| Revenue | $3.06B |
| Cost of Revenue | $1.50B |
| Gross Profit | $1.29B |
| R&D Expenses | $91.70M |
| SG&A Expenses | $824.30M |
| Operating Expenses | $2.70B |
| Operating Income | $361.50M |
| Interest Expense | $57.70M |
| Net Income | $277.30M |
| EPS (Basic) | $0.76 |
| EPS (Diluted) | $0.75 |
| Shares Outstanding (Basic) | 367.30M |
| Shares Outstanding (Diluted) | 370.10M |
Key Highlights
- 1Revenue increased by 14% to $3.10 billion in Q1 2012 compared to Q1 2011, driven by acquisitions and organic growth.
- 2Net income rose to $277.3 million ($0.75 per diluted share) in Q1 2012, up from $252.2 million ($0.64 per diluted share) in Q1 2011.
- 3Operating cash flow was strong at $392 million for the first three months of 2012.
- 4Acquisitions, notably Phadia and Dionex, contributed significantly to revenue growth.
- 5The company entered into new revolving credit facilities totaling up to $2.0 billion, enhancing its liquidity.
- 6Restructuring and other costs totaled $34 million in Q1 2012, with an additional $70 million expected for the remainder of the year.
- 7The company initiated a quarterly cash dividend of $0.13 per share, paid in April 2012.